Verastem price target lowered to $10 from $13 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Verastem to $10 from $13 saying that while the Copiktra launch progressing, the early ramp is slower than expected. The analyst, however, continues to believe in the long-term potential of Copiktra and reiterates a Buy rating on the shares.
https://thefly.com/landingPageNews.php?id=2879075